Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patients with Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions. HEOR Analyses of Real-World Dat ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2025 it granted stock options to purchase an aggregate of 40,275 ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2025 it granted stock options to purchase an aggregate of 40,275 shares of common stock and 27,144 restricted stock units ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company will host the second annual Contemporary ...

Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor ...

Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor ...

Its clinical-stage drug candidate portfolio includes omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle ...

Additionally, CYTK’s pipeline includes omecamtiv mecarbil, which is a cardiac myosin activator in a Phase 3 trial for heart failure with reduced ejection fraction. But evidently, the main value ...

Trial Demonstrates Superiority of Aficamten to Standard of Care Beta Blocker in Improving Peak Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif.